CHMP2A Antikörper (AA 1-222) (FITC)

Produktnummer ABIN7147521

Produktdetails anti-CHMP2A Antikörper (FITC)

Target: CHMP2A (Charged Multivesicular Body Protein 2A (CHMP2A))

Bindungsspezifität: AA 1-222

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser CHMP2A Antikörper ist konjugiert mit FITC

Applikation: Bitte anfragen

Kreuzreaktivität: Human

Aufreinigung: >95%, Protein G purified

Immunogen: Recombinant Human Charged multivesicular body protein 2a protein (1-222AA)

Isotyp: IgG

Anwendungsinformationen

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, PH 7.4

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C,-80 °C

Informationen zur Lagerung: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Details zu CHMP2A

Target: CHMP2A (Charged Multivesicular Body Protein 2A (CHMP2A))

Andere Bezeichnung: CHMP2A (CHMP2A Produkte)

Synonyme: BC-2 antikoerper, BC2 antikoerper, CHMP2 antikoerper, VPS2 antikoerper, VPS2A antikoerper, 1500016L11Rik antikoerper, RGD1305050 antikoerper, bc-2 antikoerper, bc2 antikoerper, chmp2 antikoerper, vps2 antikoerper, vps2a antikoerper, fj10d05 antikoerper, wu:fi18h03 antikoerper, wu:fj10d05 antikoerper, zgc:55361 antikoerper, charged multivesicular body protein 2a antikoerper, charged multivesicular body protein 2A antikoerper, Charged multivesicular body protein 2a antikoerper, charged multivesicular body protein 2A L homeolog antikoerper, ATEG_06167 antikoerper, LOC5570080 antikoerper, EDI_289610 antikoerper, PTRG_09933 antikoerper, NAEGRDRAFT_39042 antikoerper, PITG_17335 antikoerper, Tsp_00033 antikoerper, LOC100284170 antikoerper, LOC100284688 antikoerper, chm2a antikoerper, chmp2a antikoerper, CHMP2A antikoerper, Chmp2a antikoerper, chmp2a.L antikoerper

Hintergrund:

Background: Probable core component of the endosomal sorting required for transport complex III (ESCRT-III) which is involved in multivesicular bodies (MVBs) formation and sorting of endosomal cargo proteins into MVBs. MVBs contain intraluminal vesicles (ILVs) that are generated by invagination and scission from the limiting membrane of the endosome and mostly are delivered to lysosomes enabling degradation of membrane proteins, such as stimulated growth factor receptors, lysosomal enzymes and lipids. The MVB pathway appears to require the sequential function of ESCRT-O, -I,-II and -III complexes. ESCRT-III proteins mostly dissociate from the invaginating membrane before the ILV is released. The ESCRT machinery also functions in topologically equivalent membrane fission events, such as the terminal stages of cytokinesis (PubMed:21310966). Together with SPAST, the ESCRT-III complex promotes nuclear envelope sealing and mitotic spindle disassembly during late anaphase (PubMed:26040712). ESCRT-III proteins are believed to mediate the necessary vesicle extrusion and/or membrane fission activities, possibly in conjunction with the AAA ATPase VPS4.

Aliases: BC 2 antibody, BC2 antibody, Charged multivesicular body protein 2a antibody, CHM2A_HUMAN antibody, CHMP2 antibody, CHMP2a antibody, Chromatin modifying protein 2a antibody, Chromatin-modifying protein 2a antibody, hVps2 1 antibody, hVps2-1 antibody, putative breast adenocarcinoma marker antibody, Putative breast adenocarcinoma marker BC-2 antibody, Putative breast adenocarcinoma marker BC2 antibody, Vacuolar protein sorting associated protein 2 1 antibody, Vacuolar protein sorting-associated protein 2-1 antibody, Vps2 1 antibody, VPS2 antibody, Vps2-1 antibody, VPS2A antibody

UniProt: O43633

Pathways: SARS-CoV-2 Protein Interaktom